Activist investor Starboard Value has recently made a significant move by taking a stake of approximately $1 billion in Pfizer Inc. The goal behind this investment is to drive a turnaround for the struggling pharmaceutical giant, as reported by a source familiar with the situation.
Starboard has reached out to former Pfizer executives Ian Read and Frank D’Amelio for their assistance in this endeavor. Both Read and D’Amelio have shown interest in contributing to the efforts, although the specific roles they would play have not been disclosed. Read, who served as Pfizer’s CEO from 2010 to 2018, handpicked current CEO Albert Bourla as his successor. On the other hand, D’Amelio held the position of chief financial officer at Pfizer from 2007 to 2021.
The exact plans and level of engagement between Starboard and Pfizer remain unclear at this point. However, it has been revealed that the activist investor has identified investor and research analyst frustrations with the company’s ongoing struggles post-pandemic.
Pfizer, despite experiencing a surge in revenue due to its Covid-19 vaccine and treatment, has been grappling with the challenge of finding its next breakthrough product. The demand for its Covid-related products has significantly decreased, leading to a decline in the company’s stock price by more than 50% from its peak in December 2021.
Market analysts, including Mizuho’s healthcare specialist Jared Holz, have expressed skepticism about Pfizer’s ability to replace its pandemic-driven profits. The company’s stock performance this year has been lackluster, with only a marginal increase compared to the broader market.
In an attempt to bolster its product portfolio, Pfizer has turned its focus to the field of oncology. The acquisition of Seagen Inc. last year added a promising lineup of cancer drugs to its pipeline. However, setbacks in developing treatments for conditions like obesity and Duchenne muscular dystrophy have posed challenges. Additionally, Pfizer recently withdrew a drug for sickle cell anemia, which was acquired through the purchase of Global Blood Therapeutics in 2022.
Starboard has raised concerns about Pfizer’s recent acquisitions, including Biohaven and Arena Pharmaceuticals, which they believe have not yielded satisfactory results. Despite Pfizer’s cost-cutting initiatives aimed at saving $1.5 billion by 2027, Starboard highlights the contrast between the company’s current struggles and its previous positive trajectory under different leadership.
The Wall Street Journal first reported on Starboard’s involvement with Pfizer, shedding light on the activist investor’s efforts to drive change within the pharmaceutical giant. As the situation continues to unfold, stakeholders in the industry will be closely monitoring the developments to see how this partnership between Starboard and Pfizer will shape the future of the company.
